In summary, Ya-s11 demonstrates anti-RA activity, with reduced expression of osteoclast activity-related proteins TNF-α, MMP-9, cathepsin K, and TRAP and effective reduction of the clinical features of AIA. This evidence concerns the gene TNF and rheumatoid arthritis.